B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018

  • ID: 4464912
  • Report
  • 166 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Aduro BioTech Inc
  • AstraZeneca Plc
  • Bayer AG
  • Celgene Corp
  • Cell Source Inc
  • MORE
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 9, 11, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 2 molecules, respectively.

B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Aduro BioTech Inc
  • AstraZeneca Plc
  • Bayer AG
  • Celgene Corp
  • Cell Source Inc
  • MORE
Introduction
The Publisher's Report Coverage

B-Cell Chronic Lymphocytic Leukemia - Overview

B-Cell Chronic Lymphocytic Leukemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development

AB Science SA

Aduro BioTech Inc

AstraZeneca Plc

Bayer AG

BioInvent International AB

Celgene Corp

Cell Source Inc

Cellectis SA

Chugai Pharmaceutical Co Ltd

Dynavax Technologies Corp

Elsalys Biotech SAS

iDD biotech SAS

Immunomedics Inc

Juno Therapeutics Inc

Lymphocyte Activation Technologies SA

MEI Pharma Inc

Millennium Pharmaceuticals Inc

Molecular Templates Inc

Novartis AG

Noxxon Pharma AG

Ono Pharmaceutical Co Ltd

Portola Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Samumed LLC

Sunesis Pharmaceuticals Inc

TheraMAB LLC

Unum Therapeutics Inc

Xencor Inc

B-Cell Chronic Lymphocytic Leukemia - Drug Profiles

202-b - Drug Profile

2X-121 - Drug Profile

AB-8779 - Drug Profile

alemtuzumab biosimilar - Drug Profile

alisertib - Drug Profile

Aurixim - Drug Profile

AZD-4573 - Drug Profile

BI-1206 - Drug Profile

BION-1301 - Drug Profile

Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile

Cellular Immunotherapy for Hematological Malignancies - Drug Profile

Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile

Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile

Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile

Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile

Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile

Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile

Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile

cerdulatinib - Drug Profile

copanlisib hydrochloride - Drug Profile

DTRMWXHS-12 - Drug Profile

ELB-021 - Drug Profile

IDD-001 - Drug Profile

IDD-002 - Drug Profile

lenalidomide - Drug Profile

ME-401 - Drug Profile

mRNA ACTR + rituximab - Drug Profile

MT-3724 - Drug Profile

olaptesed pegol - Drug Profile

REGN-1979 - Drug Profile

SD-101 - Drug Profile

SM-08502 - Drug Profile

TAB-08 - Drug Profile

tirabrutinib - Drug Profile

tisagenlecleucel - Drug Profile

tocilizumab - Drug Profile

UCART-22 - Drug Profile

UCARTCS-1 - Drug Profile

vecabrutinib - Drug Profile

XmAb-13676 - Drug Profile

B-Cell Chronic Lymphocytic Leukemia - Dormant Projects

B-Cell Chronic Lymphocytic Leukemia - Discontinued Products

B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Aduro BioTech Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by AstraZeneca Plc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Bayer AG, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioInvent International AB, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corp, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cell Source Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cellectis SA, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corp, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Elsalys Biotech SAS, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Lymphocyte Activation Technologies SA, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by MEI Pharma Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Molecular Templates Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Novartis AG, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Portola Pharmaceuticals Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Samumed LLC, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Sunesis Pharmaceuticals Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Unum Therapeutics Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Xencor Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2018

B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2018 (Contd..1), H1 2018

B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • Aduro BioTech Inc
  • AstraZeneca Plc
  • Bayer AG
  • BioInvent International AB
  • Celgene Corp
  • Cell Source Inc
  • Cellectis SA
  • Chugai Pharmaceutical Co Ltd
  • Dynavax Technologies Corp
  • Elsalys Biotech SAS
  • iDD biotech SAS
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll